CHOSA Oncology is advancing precision medicine for platinum-based chemotherapy. Our patented Platin-DRP® technology analyses 205 tumour-specific genes to predict which patients will benefit from cisplatin or carboplatin treatment before therapy begins.

By helping clinicians identify the right patients for platinum therapy, we aim to improve treatment outcomes, increase response rates, and reduce unnecessary toxicity. 

Supported by multiple clinical studies and Key Opinion Leaders, CHOSA is committed to setting a new standard in precision oncology and transforming how platinum chemotherapy is used.

CHOSA Oncology

Org chart

Teams

Offices